Signed in as:
filler@godaddy.com
More information about licensed prescription medicines
Mounjaro (Tirzepatide)
Mounjaro (Tirzepatide)
Mounjaro (Tirzepatide)
Mounjaro is a once-weekly prescription injection used for weight loss and weight maintenance alongside a reduced-calorie diet and increased physical activity. In the UK, it is licensed for adults with a BMI of 30 or above, or a BMI of at least 27 and below 30 with a weight-related health condition. A clinician will assess whether it is su
Mounjaro is a once-weekly prescription injection used for weight loss and weight maintenance alongside a reduced-calorie diet and increased physical activity. In the UK, it is licensed for adults with a BMI of 30 or above, or a BMI of at least 27 and below 30 with a weight-related health condition. A clinician will assess whether it is suitable for you.
Tirzepatide acts on two hormone receptors, GIP and GLP-1. It helps regulate appetite, so you may feel fuller, feel less hungry and experience fewer food cravings. Treatment starts at 2.5 mg once a week. Your clinician may increase the dose gradually, allowing at least four weeks at each dose before an increase.
In the 72-week Phase 3 SURMOUNT-1 trial, people assigned to tirzepatide lost an average of 16.0% at 5 mg, 21.4% at 10 mg and 22.5% at 15 mg, compared with 2.4% for those assigned to placebo. Trial participants also received diet and activity advice. These figures are averages from adults without type 2 diabetes; individual results vary.
Common side effects include nausea, diarrhoea, vomiting, constipation and stomach pain. These are often most noticeable when starting treatment or increasing the dose and may ease over time. Vomiting or diarrhoea can cause dehydration, so contact your clinician if you cannot keep fluids down. Seek urgent medical help for severe, persistent stomach pain, particularly if it spreads to your back, as this could be pancreatitis, or for symptoms of a serious allergic reaction. Tell your clinician if you have previously had pancreatitis, have severe digestive problems or take insulin or a sulfonylurea, which can increase the risk of low blood sugar.
Mounjaro should not be used during pregnancy. If you take the oral contraceptive pill, consider using condoms as well, or changing to a non-oral method, for four weeks after starting Mounjaro and four weeks after each dose increase. If you are breastfeeding or planning to breastfeed, discuss this with your clinician before using it.
Read the full UK patient information leaflet: https://www.medicines.org.uk/emc/product/15481/pil
Wegovy (Semaglutide)
Mounjaro (Tirzepatide)
Mounjaro (Tirzepatide)
Wegovy is a prescription injection used once a week for weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity. In the UK, it is licensed for adults with a BMI of 30 or above, or a BMI of at least 27 and below 30 who also have a weight-related health condition. A clinician will assess whether
Wegovy is a prescription injection used once a week for weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity. In the UK, it is licensed for adults with a BMI of 30 or above, or a BMI of at least 27 and below 30 who also have a weight-related health condition. A clinician will assess whether it is suitable for you.
Wegovy acts like GLP-1, a hormone released after eating. It acts on areas of the brain that control appetite, helping you feel fuller, feel less hungry and experience fewer food cravings. It is injected under the skin once a week. Treatment starts at a low dose, which is increased gradually to help your body adjust.
In the 68-week Phase 3 STEP 1 trial, people assigned to the 2.4 mg weekly dose lost an average of 14.9% of their starting body weight, compared with 2.4% for those assigned to placebo. Everyone in the trial also received advice on reducing calorie intake and increasing activity. Individual results vary.
Common side effects include nausea, vomiting, diarrhoea, constipation, stomach pain, indigestion, headache and tiredness. These can be more noticeable when the dose is increased and often ease over time. Vomiting or diarrhoea can cause dehydration, so contact your clinician if you cannot keep fluids down. Stop using Wegovy and seek urgent medical help if you develop severe, persistent stomach pain, with or without vomiting, as this could be pancreatitis. Seek urgent advice for a serious allergic reaction or sudden loss or worsening of vision. Tell your clinician about your medical conditions and other medicines, particularly if you have diabetes or take insulin or a sulfonylurea. Wegovy should not be used during pregnancy or breastfeeding; if you plan to become pregnant, discuss stopping it at least two months beforehand.
Read the full UK patient information leaflet for the Wegovy injection:https://www.medicines.org.uk/emc/product/13803/pil
Saxenda (Liraglutide)
Mounjaro (Tirzepatide)
Saxenda (Liraglutide)
Saxenda is a once-daily prescription injection used for weight management alongside a reduced-calorie diet and increased physical activity. In adults, it is licensed for people with a BMI of 30 or above, or a BMI of at least 27 with a weight-related health condition. A clinician will assess whether it is suitable for you.
Saxenda acts like
Saxenda is a once-daily prescription injection used for weight management alongside a reduced-calorie diet and increased physical activity. In adults, it is licensed for people with a BMI of 30 or above, or a BMI of at least 27 with a weight-related health condition. A clinician will assess whether it is suitable for you.
Saxenda acts like GLP-1, a hormone released after eating. It acts on areas of the brain that regulate appetite, helping you feel fuller and less hungry so you may find it easier to eat less. You inject it under the skin once a day. The dose starts at 0.6 mg and is usually increased gradually each week to 3 mg daily.
In a 56-week clinical trial, people taking Saxenda lost an average of 8.0% of their starting body weight, compared with 2.6% for those taking a placebo. Everyone in the trial also received advice on diet and activity. Individual results vary. Under the UK licence, treatment should be stopped if you have not lost at least 5% of your starting weight after 12 weeks at the 3 mg daily dose.
The most common side effects are nausea, vomiting, diarrhoea, constipation and headache. These often improve after the first few days or weeks. Vomiting and diarrhoea can cause dehydration, so contact your clinician if you cannot keep fluids down. Seek urgent medical advice for severe, persistent stomach pain, particularly if it spreads to your back, as this could be pancreatitis. Tell your clinician about any gallbladder problems, diabetes medicines or other medical conditions before starting. Saxenda should not be used during pregnancy or breastfeeding.
Read the full UK patient information leaflet: https://www.medicines.org.uk/emc/product/2313/pil
Oral medications
Mysimba
Mysimba is a prescription tablet used to help manage weight alongside a reduced-calorie diet and increased physical activity. In the UK, it is licensed for adults with a BMI of 30 or above, or a BMI of at least 27 and below 30 who also have a weight-related condition, such as type 2 diabetes, abnormal blood fats or controlled high blood pressure. A clinician will assess whether it is suitable for you.
Mysimba contains two medicines, naltrexone and bupropion. Together, they act on areas of the brain involved in food intake and appetite. The dose is increased gradually over four weeks. Tablets should be swallowed whole, preferably with food, and taken exactly as prescribed.
In three clinical studies, average weight loss with Mysimba was around 3.7% to 5.7%, compared with 1.3% to 1.9%with a placebo. In a separate study with more intensive support, average weight loss was 8.1% with Mysimba and 4.9%with placebo. Results vary between individuals. Treatment should be stopped after 16 weeks if you have not lost at least 5% of your starting weight, and your clinician will review whether it remains suitable each year.
The most common side effects are nausea, vomiting, constipation and headache. Some people also experience dizziness, anxiety, difficulty sleeping, a dry mouth or an increase in blood pressure or heart rate. Your blood pressure and pulse should be checked before and during treatment. Mysimba is unsuitable for some people, including those with uncontrolled high blood pressure, a history of seizures, bipolar disorder or certain eating disorders. It must not be taken with opioid medicines, including some painkillers and cough medicines, because naltrexone blocks their effects. Tell your clinician about all medicines you take and any mental health concerns. Seek urgent medical advice if you have a seizure, develop thoughts of harming yourself or have a serious allergic or skin reaction. Mysimba should not be used during pregnancy or breastfeeding.
Read the full UK patient information leaflet: https://www.medicines.org.uk/emc/product/2684/pil
Orlistat
Orlistat is a weight management medicine taken with meals. The prescription-strength 120 mg capsule is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 28 or above with weight-related risk factors. It is used alongside a reduced-calorie diet. A clinician will check whether it is suitable for you.
Orlistat works in the gut by blocking some of the enzymes that break down fat from food. This means that some of the fat you eat is not absorbed and passes out in your stool. It does not work by reducing appetite. The usual 120 mg dose is one capsule immediately before, during or up to one hour after each main meal. Skip the capsule if you miss a meal or the meal contains no fat.
In clinical studies, 20% of people taking orlistat 120 mg lost at least 10% of their starting weight after one year, compared with 8% taking a placebo. Weight loss varies between individuals. Under the product licence, treatment should be stopped after 12 weeks if you have not lost at least 5% of your starting weight.
The most common side effects are oily or fatty stools, wind, an urgent need to open your bowels and oily leakage. These effects are more likely after a high-fat meal. Orlistat can also reduce absorption of vitamins A, D, E and K, so your clinician may recommend a multivitamin taken at a different time of day. Tell your clinician about all your medicines, particularly warfarin or other blood thinners, ciclosporin, thyroid medicine or epilepsy medicine. Orlistat is not suitable for everyone, including people who are pregnant or breastfeeding or who have certain conditions affecting fat absorption or bile flow.
Read the full UK patient information leaflet for the 120 mg capsules:https://www.medicines.org.uk/emc/product/2592/pil
Foundayo (orforglpron)
Foundayo is a once-daily prescription tablet used for weight loss and to help maintain weight loss. In the UK, it is licensed for adults with a BMI of 30 or above, or a BMI of at least 27 and below 30 who also have a weight-related health condition. It is used alongside a reduced-calorie diet and increased physical activity. A clinician will assess whether it is suitable for you.
Foundayo acts on the GLP-1 receptor, mimicking a hormone released after eating. It helps regulate appetite, so you may feel fuller, feel less hungry and find it easier to eat less. The tablet can be taken at any time of day, with or without food. Your dose is increased gradually according to your clinician’s instructions.
In a Phase 3 trial, people taking the highest studied dose lost an average of 12.4% of their starting body weight after 72 weeks, compared with 0.9% for people taking a placebo. These are trial averages, and individual results vary.
The most common side effects are nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain. These symptoms are often more noticeable when starting treatment or increasing the dose. Vomiting or diarrhoea can cause dehydration, so contact your clinician if symptoms persist or you cannot keep fluids down. Seek medical help immediately if you develop severe, persistent stomach pain, especially if it spreads to your back. Tell your clinician about your medical conditions and other medicines before starting. Foundayo should not be used during pregnancy or breastfeeding; it may also make the oral contraceptive pill less effective when treatment starts and after dose increases.
Read the full UK patient information leaflet before taking Foundayo:https://www.medicines.org.uk/emc/product/102531/pil
Wegovy Pill (oral semaglutide)
Wegovy tablets (semaglutide)
Wegovy tablets are a once-daily prescription medicine used for weight loss and weight maintenance alongside a reduced-calorie diet and increased physical activity. In the UK, they are licensed for adults with a BMI of 30 or above, or a BMI of at least 27 and below 30 with a weight-related health condition. A clinician will assess whether they are suitable for you.
Semaglutide acts like GLP-1, a hormone released after eating. It acts on areas of the brain that regulate appetite, helping you feel fuller, feel less hungry and experience fewer food cravings. The dose starts low and is increased gradually, usually each month, to the recommended 25 mg daily dose.
How you take the tablet matters. Take it on an empty stomach after fasting for at least 8 hours. Swallow it whole with a sip of water, up to 120 mL. Then wait at least 30 minutes before eating, drinking or taking any other medicine by mouth. Taking it differently may reduce how much semaglutide your body absorbs.
In the 64-week Phase 3 OASIS 4 trial, people assigned to Wegovy 25 mg tablets lost an average of 13.6% of their starting body weight, compared with 2.2% for those assigned to placebo. Everyone in the trial was also advised to reduce calorie intake and increase physical activity. These are averages; individual results vary.
Common side effects include nausea, vomiting, diarrhoea, constipation, stomach pain, indigestion, headache and tiredness. Vomiting or diarrhoea can cause dehydration, so contact your clinician if you cannot keep fluids down. Stop taking the medicine and seek urgent medical help if you develop severe, persistent stomach pain, with or without vomiting, as this could be pancreatitis. Seek urgent advice for a serious allergic reaction or sudden loss or worsening of vision. Tell your clinician if you have diabetes, particularly if you use insulin or a sulfonylurea, or if you take other regular medicines. Wegovy tablets should not be used during pregnancy or breastfeeding. If you are planning a pregnancy, discuss treatment with your clinician: semaglutide should be stopped at least two months beforehand.
Read the full UK patient information leaflet for Wegovy tablets:https://www.medicines.org.uk/emc/product/102344/pil
Your Journey to success ebook
Weight Loss Wales publications
Innovative digital weight management: real-world outcomes from Weight Loss Wales
LBP4.086
Innovative Digital Weight Management: Real-World Outcomes
from Weight Loss Wales
Davies, A. L.
Clinical Director, Weight Loss Wales, United Kingdom
Obesity remains a significant public health burden in the UK, with prev-
alence continuing to rise, leading to increased rates of type 2 diabetes,
cardiovascular disease, and reduced quality of life. Despite the growing
availability of pharmacological treatments, adherence to anti-obesity
medications remains a challenge, necessitating smarter, more innovative
approaches to ensure safe and effective weight management.
Weight Loss Wales became the first Healthcare Inspectorate Wales accred-
ited and approved virtual weight management clinic in Wales, utilizing
a fully digital approach to patient consultations. By integrating virtual
assessments with close, ongoing patient engagement via WhatsApp, text
messaging, and email, the service provided continuous support while
optimizing adherence to treatment.
This study presents real-world data from the first 100 patients initiated on
semaglutide or tirzepatide for weight management. Key findings include:
• 96% of patients remained on treatment for at least six months.
• The average weight loss at six months was 19kg, demonstrating signif-
icant efficacy.
• The average dose of tirzepatide used was 7.7mg, highlighting a gradual
patient centric titration approach within a virtual setting.
Davies, A.L. (2025) ‘Innovative digital weight management: real-world outcomes from Weight Loss Wales’, Obesity Facts, 18(Suppl 1), p. LBP4.086. Presented at the 32nd European Congress on Obesity (ECO 2025), Málaga, Spain, 11–14 May. doi:10.1159/000545968.
12-Month Real-World Outcomes
Davies, A.L. et al. (2025) ‘12-Month Real-World Outcomes From Wales’ First Fully Accredited Remote Obesity Clinic’, ObesityWeek 2025, Atlanta, GA, USA, 5 November. Poster presentation (Poster 264).LBP4.086
Background:
Obesity remains a major contributor to chronic disease in the UK, driving increased rates of type 2 diabetes, cardiovascular events, and healthcare system strain. The advent of GLP-1 receptor agonists, such as semaglutide, marked a significant advancement in pharmacological weight management. More recently, the introduction of dual GIP/GLP-1 receptor agonists, such as tirzepatide (launched in the UK in February 2024), has offered further promise, delivering greater efficacy through combined hormonal pathways. However, real-world data evaluating long-term outcomes, persistence, and tolerability—particularly within virtual care models—remain limited. Objective: To evaluate 12-month real-world outcomes from Weight Loss Wales, Wales’ first fully remote, Healthcare Inspectorate Wales-accredited obesity clinic, in patients initiated on semaglutide or tirzepatide during the first year of dual once-weekly therapy availability in the UK.
Methods:
Between February 2024 and February 2025, the first 100 patients who were initiated on semaglutide or tirzepatide and managed entirely remotely were followed up. Care included digital onboarding, virtual consultations, monthly reviews, and open clinician access via WhatsApp, SMS, and email. Consultations included education on the mechanism of action, expected effects, and side effect management strategies. Clinical outcomes, treatment persistence, dose adjustment, safety, and healthcare utilisation were assessed and benchmarked against STEP and SURMOUNT trial data.
Results:
• 91% of patients remained on therapy at 12 months, demonstrating strong long-term persistence. • Of the 9% who discontinued, only 2% did so due to side effects, while 7% discontinued due to financial constraints. • Average weight loss was 24.8kg, sustained across the cohort. • 23% of patients required a dose de-escalation at some point over the 12-month treatment period, typically in response to tolerability or patient preference. • Patients initiated an average of 3.2 clinical contacts per month, excluding administrative or medication-related interactions, supported via WhatsApp. • No A&E attendances or primary care consultations related to treatment were recorded. • No prescriptions were required for the management of side effects, indicating effective anticipatory support and minimal need for adjunctive interventions. • These real-world results compare favourably with discontinuation rates due to side effects seen in SURMOUNT-1 (6.2%) and STEP-1 (4.5%).
Conclusions:
This first-year evaluation following the UK introduction of tirzepatide demonstrates that a fully remote model of obesity care can deliver high treatment retention, substantial weight loss, and excellent tolerability. The low discontinuation rate for side effects (2%), absence of healthcare resource use, and no requirement for side-effect prescriptions reflect the success of early, accessible, and proactive support. Importantly, careful consultation—including explanation of mechanism of action and anticipatory guidance—may have contributed to improved adherence and patient confidence. These findings confirm that remote care, when structured and supported by direct clinician access, is not substandard—it is gold standard. Weight Loss Wales offers a scalable, effective, and sustainable blueprint for delivering high-quality obesity management across the NHS and beyond.
Davies, A.L. et al. (2025) ‘12-Month Real-World Outcomes From Wales’ First Fully Accredited Remote Obesity Clinic’, ObesityWeek 2025, Atlanta, GA, USA, 5 November. Poster presentation (Poster 264).
Davies, A.L. et al. (2025) ‘MoA Education Reduces Side Effects and Enhances Persistence in Remote Ob
Background:
GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have transformed obesity pharmacotherapy, offering clinically significant weight loss. However, gastrointestinal side effects remain a leading cause of treatment discontinuation in clinical trials and real-world settings. While virtual care offers accessible treatment models, concerns persist about adequate support and patient retention. Patient understanding of the mechanism of action (MoA) may be a critical but under-recognised driver of adherence and tolerability.
Methods:
This observational analysis examined outcomes from the first 100 patients initiated on semaglutide or tirzepatide at Weight Loss Wales, the first fully remote, Healthcare Inspectorate Wales-accredited obesity clinic following the launch of the 2nd once weekly agent indicated for weight management in the UK . Between February 2024 and February 2025, patients received structured education explaining the mechanism of action, titration, and anticipated side effects during virtual consultations. Ongoing support was provided via WhatsApp, SMS, and email, allowing rapid intervention and real-time communication. Clinical outcomes, persistence, healthcare utilisation, and use of adjunctive medications were assessed and benchmarked against published STEP-1 and SURMOUNT-1 trial discontinuation rates.
Results:
At 12 months, 91% of patients remained on therapy. Only 2% discontinued due to side effects, significantly lower than rates in SURMOUNT-1 (6.2%) and STEP-1 (4.5%). No prescriptions for antiemetics or other side-effect management medications were required. Dose de-escalation occurred in 23% of patients, typically in response to patient-reported tolerability issues, addressed proactively. The average weight loss was 24.8 kg. No A&E attendances or primary care consultations related to treatment were recorded.
Conclusions:
Structured education on mechanism of action and proactive, accessible clinician communication were associated with reduced discontinuation, fewer side effects, and no requirement for adjunctive prescribing. These findings support the hypothesis that informed patients are more adherent and better prepared to manage treatment expectations. Remote care, when grounded in education and real-time support, can match or exceed traditional models in safety, tolerability, and persistence.
Davies, A.L. et al. (2025) ‘MoA Education Reduces Side Effects and Enhances Persistence in Remote Obesity Treatment’, ObesityWeek 2025, Atlanta, GA, USA, 5 November. Poster presentation (Poster 265)
Acquisition costs and weight reduction
Evans, M., Evans, W., Godbeer, F., Edgar, L., Spaepen, E. and Davies, A.L. (2025) ‘Analysis of tirzepatide acquisition costs and weight reduction outcomes in the United Kingdom: insights from the SURMOUNT-1 study’, Advances in Therapy, 42(6), pp. 2821–2832. doi:10.1007/s12325-025-03194-8.
Wang, W., Chen, R., Lloyd Davies, A., Guo, J., Bo Jensen, T., Li, Y., Luo, B., Ye, X., Zhang, K. and Ning, G. (2023)‘IDF2022-0613 PIONEER 11: Efficacy and safety of oral semaglutide versus placebo in predominantly Chinese patients with T2D treated with diet and exercise’, Diabetes Research and Clinical Practice, 197 (Suppl 1), 110316. doi:10.1016/j.diabres.2023.110316.
Knop, F.K., Cariou, B., Christiansen, E., Davies, A.L., Montanya, E., Abildlund, M.T. & Rosenstock, J. (2021) ‘Time spent in glycaemic control after initiating treatment with oral semaglutide vs empagliflozin: an exploratory analysis of the PIONEER 2 trial’. 57th Annual Meeting of the European Association for the Study of Diabetes (EASD 2021), Abstract 480, pp. 249–250.
Davies, A.L., Khunti, K., Capehorn, M., Artime, E., Spaepen, E., Adam, A., Lin, X., Shang, M., Seager, S. and von Arx, L.-b. (2024) ‘The UK Obesity Landscape: Results from the UK Primary Care Cohort of the IMPACT-O Study’, International Journal of Obesity, 48(Suppl 1), P84. doi:10.1038/s41366-023-01431-0.
PDF Viewer
Mounjaro v Wegovy
Tirzepatide 10 and 15 mg were associated with statistically significant
greater reductions in weight, BMI and HbA1c versus semaglutide.
PDF Viewer
Mounjaro v Wegovy
The pooled analysis showed greater
weight loss with tirzepatide compared to semaglutide
PDF Viewer
File coming soon.
Practical tips
The most common side effects observed in clinical trials were nausea and diarrhoea, these were mild/moderate in severity, and usually of short duration and most frequently reported during the first few months on treatment.
- Try: Eating smaller portions
- Try: Eating slowly
- Try: to stay hydrated
- Try: To stop eating at first sign of fullness
- Avoid: Large portions
- Avoid: Fried or fatty foods
- Avoid: Overly sweet or spicy foods
- Avoid: Drinking alcohol and smoking cigarettes
Read the patient leaflet and information you have been provided and contact us on the number you have been given or via the contact us page.
What to expect after 4th dose of Tirzepatide is given
Following the 4th dose of Tirzepatide there will be a quantity of solution left in the pen device.
Weight loss is difficult but its not your fault
Evidence for diet and exercise
Patients have the autonomy to choose their preferred exercise modality, thereby optimizing treatment outcomes. In addition, this novel systematic review included a dose-response meta-analysis, which showed that aerobic exercise required 140 min per week to improve depressive symptoms
Privacy Policy
Privacy Policy
Effective: January 3, 2026
Contents
1. ABOUT US
2. ABOUT THIS PRIVACY POLICY
3. WHAT PERSONAL INFORMATION WE COLLECT AND HOW WE COLLECT IT?
4. HOW WE USE YOUR PERSONAL INFORMATION?
5. WHAT IS OUR LEGAL BASIS FOR PROCESSING?
6. HOW WE SHARE YOUR PERSONAL INFORMATION?
7. YOUR MARKETING CHOICES
8. RETENTION OF YOUR DATA AND DELETION
9. INTERNATIONAL TRANSFERS
10. YOUR DATA PROTECTION RIGHTS
11. CHANGES TO THIS PRIVACY POLICY
12. CONTACT US
1. ABOUT US
“We”, “us” or “our” means Weight Loss Wales, with its principal place of business located at 3 Dan-Y-Bryn Close Radyr Cardiff South Glamorgan GB CF15 8DJ.
2. ABOUT THIS PRIVACY POLICY
Your privacy is important to us, so we’ve developed this Privacy Policy, which explains how we collect, use, and disclose your personal information. We collect personal information when you use our website(s), mobile apps, and other online and offline products, services and experiences (collectively, the “Services”). Please take a moment to read through this Policy in its entirety.
If you have any questions, concerns or complaints regarding this Privacy Policy or how we use your personal information please contact us via e-mail at enquiries@weightlosswales.com.
3. WHAT PERSONAL INFORMATION WE COLLECT AND HOW WE COLLECT IT?
We collect personal information that you provide directly to us:
Contact information. If you sign up to receive our newsletter, emails, or text messages from us, we will collect your name, email address, mailing address, phone number, and any other information needed to contact you about the Services.
Payment information. To order products or services through the Services, you will need to provide us with payment information (like your bank account or credit card information). Please note that your financial information is collected and stored by a third party payment processing company. Use and storage of that information is governed by the third party payment processor’s applicable privacy policy.
Survey information. You may provide us with other personal information when you fill in a form, respond to our surveys or questionnaires, provide us with feedback, participate in promotions, or use other features of the Services.
Communications information. We may also collect other information during our communications with you, including information that you send to us when interacting with our customer service agents, or when you call us or send emails or text messages. This may include information about how you contacted us, your marketing preferences, and other information that you choose to share.
4. HOW WE USE YOUR PERSONAL INFORMATION?
We use the personal information we collect for the following reasons:
- To send you our newsletter, or other information or marketing about our Services that you think may be of interest to you.
- To reply to your questions, inquiries, or customer service requests or to send you notices, updates, security alerts, or support and administrative messages.
- To provide you with information about the Services that you request from us or which we feel may interest you.
- To monitor and analyze trends, usage and activities in connection with our Services and to improve the Services.
- To facilitate contests, sweepstakes and promotions, and to process entries and provide prizes and rewards.
- To detect, investigate and prevent fraudulent transactions and other illegal activities on the Services and to protect the rights and property of us and our customers.
- To carry out our obligations arising from any contracts entered into between you and us, including for billing and collection.
We may also use your personal information to fulfill our obligations as set out by the applicable law, or to carry out any other purpose as described to you at the time your personal information was collected.
5. WHAT IS OUR LEGAL BASIS FOR PROCESSING?
In certain countries we are required to have a legal basis for collecting and using your personal information.Our legal basis will depend on the personal information concerned and the specific context in which we collect it. We will normally collect personal information from you only where we have your consent to do so, where we need your information to perform a contract with you, or where the processing is in our legitimate interests and not overridden by your fundamental rights. In some cases, we may also have a legal obligation to collect personal information from you or may otherwise need the personal information to protect your vital interests or those of another person.
If you have questions about or need further information concerning the legal basis on which we collect and use your personal information, please contact us using the details provided in the “Contact Us” section below.
6. HOW WE SHARE YOUR PERSONAL INFORMATION?
We may share your personal information in the following ways:
- With vendors, consultants, and other service providers who process your personal information on our behalf when they provide services to us, for example data analytics, research, marketing and financial services.
- In connection with, or during negotiations of, any merger, sale of company assets, financing or acquisition of all or a portion of our business by another company.
We may be legally required to disclose or share your personal information without your consent in some circumstances, for example to comply with a court order or law enforcement. In such circumstances, we will only disclose your personal information if we have a good-faith belief that such sharing is required under applicable legal obligations.
7. YOUR MARKETING CHOICES
When you sign up for a promotion like a sweepstakes, or subscribe to receive our newsletter or marketing/promotional messages, we use your personal information to help us decide which products, services and offers may be of interest to you.
We will send marketing messages to you if you have asked us to send you information, bought goods or services from us, or if you provided us with your details when you entered a competition or registered for a promotion. If you opt out of receiving marketing messages, we may still send you non-promotional emails. We will ask for your consent before we share your personal information with any third party for their direct marketing purposes.
You may unsubscribe from marketing messages through a link we include on messages we send you. You can also ask us to stop sending you marketing messages at any time by contacting us at: enquiries@weightlosswales.com.
8. RETENTION OF YOUR DATA AND DELETION
Your personal information will not be kept longer than is necessary for the specific purpose for which it was collected.
When we decide how long we will keep your information we consider the amount, nature, and sensitivity of the personal information, the potential risk of harm from unauthorized use or disclosure, why we need it, and any relevant legal requirements (such as legal retention and destruction periods).
The foregoing will, however, not prevent us from retaining any personal information if it is necessary to comply with our legal obligations, in order to file a legal claim or defend ourselves against a legal claim, or for evidential purposes.
Details of retention periods for different aspects of your personal data are available from us on request by contacting us using the contact details provided under the “Contact Us” heading below.
9. INTERNATIONAL TRANSFERS
We will ensure that any transfer of personal information to countries outside of the United States will take place pursuant to the appropriate safeguards.
10. YOUR DATA PROTECTION RIGHTS
Depending on the circumstances, you may have some of the following rights under applicable data protection laws. To exercise any of them, please contact us using the details provided in the “Contact Us” section below
- You may access, correct, or request deletion of your personal information
- You may object to processing of your personal information, ask us to restrict processing of your personal information or request portability of your personal information, (i.e. your data to be transferred in a readable and standardized format).
- If we have collected and processed your personal information with your consent, then you can withdraw your consent at any time.
We respond to all requests we receive from individuals wishing to exercise their data protection rights in accordance with applicable data protection laws.
You may also have the right to complain to a supervisory authority about our collection and use of your personal data. For more information, please contact your local supervisory authority.
11. CHANGES TO THIS PRIVACY POLICY
From time to time, we have the right to modify this Privacy Policy. We’re likely to update this Privacy Policy in the future and when we make changes. When we update this Privacy Policy, we will take appropriate measures to inform you, consistent with the significance of the changes we make.Please come back and check this page from time to time for the latest information on our privacy practices.
12. CONTACT US
The data controller of your personal information is Weight Loss Wales.
If you have questions or concerns about the information in this Privacy Policy, our handling of your personal information, or your choices and rights regarding such use, please do not hesitate to contact us at:
Weight Loss Wales
S Policy
Weight Loss Wales
Messaging Terms & Conditions
Weight Loss Wales
General
When you opt-in to the service, we will send you a message to confirm your signup.
By opting into messages, you agree to receive recurring automated marketing and informational text messages from Weight Loss Wales. Automated messages may be sent using an automatic telephone dialing system to the mobile telephone number you provided when signing up or any other number that you designate.
Message frequency varies, and additional mobile messages may be sent periodically based on your interaction with Weight Loss Wales. Weight Loss Wales reserves the right to alter the frequency of messages sent at any time to increase or decrease the total number of sent messages. Weight Loss Wales also reserves the right to change the short code or phone number or alphanumeric sender where messages are sent
Your usual message and data rates may apply. If you have any questions about your text plan or data plan, it is best to contact your mobile provider. Your mobile provider is not liable for delayed or undelivered messages.
Your consent to receive marketing messages is not a condition of purchase.
Carriers
Carriers are not liable for delayed or undelivered messages.
Cancellation
Messages will provide instructions to unsubscribe either by texting STOP or through an included link. After you unsubscribe, we will send you a message to confirm that you have been unsubscribed and no more messages will be sent. If you would like to receive messages from Weight Loss Wales again, just sign up as you did the first time and Weight Loss Wales will start sending messages to you again.
Info
For support regarding our services, email us at enquiries@weightlosswales.com or, if supported, text \"HELP\" to our messages at any time and we will respond with instructions on how to unsubscribe. If we include a link in messages we send you from Weight Loss Wales, you may also access instructions on how to unsubscribe and our company information by following that link.
Transfer of Number
You agree that before changing your mobile number or transferring your mobile number to another individual, you will either reply \"STOP\" from the original number, unsubscribe using the link included in our messages (if one is provided), or notify us of your old number at enquiries@weightlosswales.com. The duty to inform us based on the above events is a condition of using this service to receive messages.
Privacy
If you have any questions about your data or our privacy practices, please visit our http://eepurl.com/jv68pQ.
Messaging Terms Changes
We reserve the right to change or terminate our messaging program at any time. We also reserve the right to update these Messaging Terms at any time. Such changes will be effective immediately upon posting. If you do not agree to a change to these Messaging Terms, you should cancel your enrollment with our messaging program. Your continued enrollment following such changes shall constitute your acceptance of such changes.
Safeguarding
Weight Loss Wales is committed to preventing and responding to risks of harm to and promoting the welfare of all adults at risk that we work with (i.e. as Weight Loss Wales’s patients).
We recognise the importance of this commitment to safety and welfare and, further, are committed to safeguarding all patients without discrimination due to an individual’s age, disability, race, religion or belief, sex, gender reassignment, pregnancy or maternity leave status, marriage or civil partnership status, or sexual orientation. This Safeguarding Policy is based on the safeguarding laws of England, Wales, and Scotland, including related guidance issued by the UK Government and relevant governmental departments, agencies, and public bodies. If this Policy is at any time inconsistent with this body of law, Weight Loss Wales will act to meet the requirements of up-to-date safeguarding laws in priority to the requirements set out in this Policy.
Weight Loss Wales has implemented this Safeguarding Policy in order to meet its obligations as an organisation working with adults at risk. Any questions in relation to this Policy should be referred to us by emailing enquiries@weightlosswales.com. Staff Members will receive safeguarding training that should enable them to identify Safeguarding Concerns (e.g. suspected abuse, neglect, or threats to wellbeing) relevant to Weight Loss Wales’s patients. If a Staff Member identifies a Safeguarding Concern, to report it they should: Follow appropriate steps as would be expected of a healthcare professional by informing Police, social services or the patients' own GP. If a Staff Member feels unable to follow the above steps, they should report their Safeguarding Concern in a reasonable alternative manner. This may the case if, for example: Following the above procedure would require disclosing the concern to somebody who is implicated in the Safeguarding Concern or who the Staff Member is otherwise uncomfortable contacting about this concern, or The matter is time sensitive and involves a risk of serious harm to somebody, in which case contacting an external agency (e.g. the police, the ambulance service, or a mental health crisis line) or a more senior member of Weight Loss Wales’s staff first may be more appropriate.
How to raise a concern or make a complaint
Help us to help you
Making a complaint
At Weight Loss Wales, we strive for quality. It is our priority to put safety, expertise, and patient health at the core of everything we do. As a leader in the weight loss industry, we aim to deliver exceptional levels of care and customer service to all our patients and customers.
When you feel our service has not met your expectations it’s imperative for us to know so that we may provide resolution and continually improve our care and service delivery.
To raise a concern
We are keen to resolve your concern at the time it occurs, ensuring the rest of your visit is as worry-free as possible.
Should you have any concerns, please raise these directly with the member of staff caring for you. Our staff may need to escalate your feedback for further intervention or support. Should you have any concerns following your consultation, please contact us as we welcome the opportunity to help and act to resolve your concern efficiently.
Making a formal complaint
A complaints procedure is in place for patients who may not be satisfied with our services and wish to make a formal complaint. In the event you wish to make a written complaint please write to us (either by email or by contact page on our website no later than six months after the incident occurred. All comments and complaints are investigated thoroughly and are confidential.
Your letter should include a summary of your concerns and both where and when the events took place.
When a relative or friend wishes to raise a concern or complaint on your behalf we will require written consent from you before we can discuss information related to your care, in order to ensure your confidentiality is protected.
Weight Loss Wales will also share a summary of the complaint with you as it is important for you to understand the contents of the concern being raised. During the investigation into your complaint, we will share your concerns with relevant staff to help us consider your feedback and provide you with a response.
If you do not wish for us to contact the relevant staff or consultant, please do let us know although this will limit our investigation on your behalf.
Stage 1 – Local Resolution
- Upon receipt of your complaint, you will receive a written acknowledgement within two working days unless a full response can be sent to you within five working days.
- If we cannot provide you with a written response within five working days, we will aim to provide you with a response within 20 working days of the date of your complaint.
- If we cannot provide you with a full response within 20 working days, we will write to you notifying you of any delays. In this situation we will regularly update you on the progress of your complaint.
Stage 2- External feedback
If you remain dissatisfied with the way the complaint has been handled you may consider contacting Healthcare Inspectorate Wales (HIW) to Provide feedback about a healthcare service.
Provide feedback about a healthcare service | Healthcare Inspectorate Wales (hiw.org.uk)
HIW are responsible for checking that anyone who provides a healthcare service (NHS or private/independent) in Wales meets the required standards of quality & safety.
Even though their statutory role does not routinely include investigating individual concerns or complaints or the particular circumstances of a patient’s care and treatment, they would still like to hear from you if you have concerns about healthcare services.